Has Steven Reynolds, DO received payments from drug or device companies?

Yes. Drug and device makers reported $53,003,809 in general payments to Steven Reynolds, DO across 1,015 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Steven Reynolds, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Steven Reynolds, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Steven Reynolds, DO

Family Medicine · Long Beach, CANPI 1700893294

Payments from drug & device makers

$53,003,809in general payments, 2019–2025

Across 1,015 payments — averaging $52,221 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$14.4M
Amgen$12.4M
Ipsen Bioscience Inc.$4.9M
Pfizer$4.5M
AbbVie$4.3M
E.r. Squibb & Sons, L.L.C.$3.3M
plus $9.2M from 49 others

$5,137in research payments, 2019–2025

Across 3 payments — averaging $1712.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$5K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	37	$14,398,761
Amgen(2 entities)	14	$12,421,949
Ipsen Bioscience Inc.	76	$4,927,582
Pfizer	164	$4,453,409
AbbVie	76	$4,266,999
E.r. Squibb & Sons, L.L.C.	4	$3,319,937
Deciphera Pharmaceuticals Inc.	28	$1,986,149
Astrazeneca UK Limited	4	$1,902,518
Bristol Myers Squibb	6	$1,045,104
Modernatx, Inc.	19	$763,500
H. Lundbeck A S	1	$645,403
Sanofi Pasteur Inc.	13	$644,986
Bayer	7	$478,491
GSK	15	$452,078
Alkermes, Inc.	6	$317,547
Biontech SE	37	$263,802
Sanofi US Services Inc.	5	$173,313
AstraZeneca	27	$172,787
Biohaven Pharmaceuticals, Inc.	15	$136,803
Alnylam Pharmaceuticals Inc.	248	$93,020
Biohaven Pharmaceutical Holding Company Ltd.	6	$52,267
Sanofi	11	$33,997
Novartis	3	$20,312
Eagle Pharmaceuticals, Inc.	1	$16,020
Merck	11	$13,184
Gilead	43	$987
Lilly USA, LLC	24	$522
Johnson & Johnson	20	$400
Antares Pharma, Inc.	16	$294
Eisai Inc.	10	$218
Otsuka America Pharmaceutical, Inc.	9	$211
Boehringer Ingelheim	6	$127
Amarin Pharma, Inc.	5	$113
Boston Scientific	4	$107
Idorsia Pharmaceuticals US Inc	6	$100
Halozyme Inc	4	$97
Astellas Pharma US Inc	4	$89
Bausch Health US, LLC	4	$81
Abbott	2	$58
Novo Nordisk	4	$51
Takeda Pharmaceuticals U.S.A., Inc.	3	$49
Teva Pharmaceuticals USA, Inc.	2	$39
Aytu Biopharma, Inc.	1	$37
Verity Pharmaceuticals Inc.	1	$36
Viiv Healthcare Company	1	$34
Dexcom, Inc.	1	$34
Tolmar, Inc.	2	$32
Kowa Pharmaceuticals America, Inc.	2	$28
Exact Sciences	1	$24
SK Life Science, Inc.	1	$24
Azurity Pharmaceuticals, Inc.	1	$23
Optinose US, Inc.	1	$22
Inspire Medical Systems, Inc.	1	$22
Neuronetics, Inc.	1	$21
Lundbeck LLC	1	$16

How this compares

$53,003,809 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Medicare billing

Part B allowed, 2024

$193,682

Medicare patients

287

Services billed

10,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Long Beach

Jack VuLong Beach$10.1M
Amina HaggagNorthridge$112.8M
Rizwana MohseniLake Forest$26.7M
Daniel JohnsonSan Diego$15.7M
Stacey LayleSan Diego$14.8M
Apinya VutikullirdCypress$14.3M
Hanid AudishSpring Valley$13.6M
Augusto FocilOxnard$12.6M
Suzanne FussellOxnard$8.9M
Joanna vanColton$8.6M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →